medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Número 2

<< Anterior Siguiente >>

Rev Invest Clin 2006; 58 (2)


Parámetros de práctica para el manejo del dolor neuropático

Guevara-López U, Covarrubias-Gómez A, García-Ramos G, Hernández-Jiménez S

Idioma: Español
Referencias bibliográficas: 88
Paginas: 126-138
Archivo PDF: 92.10 Kb.


RESUMEN

El dolor neuropático (DN) es una entidad heterogénea con una sintomatología diversa. Las controversias existentes respecto a su definición y clasificación dificultan conocer su epidemiología, a pesar de esto se ha estimado que cerca de cuatro millones de personas en Estados Unidos son portadoras de este problema médico. Objetivo. Se conformó un grupo de consenso con la finalidad de crear recomendaciones médicas que faciliten la toma de decisiones y el abordaje terapéutico del mismo. Método. Se realizó una búsqueda en la literatura en diferentes bases de datos electrónicas (MEDLINE, EMBASE, COCHRANE). Se efectuaron tres sesiones de trabajo en las cuales se evaluaron las evidencias médicas científicas sobre el diagnóstico y tratamiento de la polineuropatía diabética dolorosa, la neuralgia postherpética y neuralgia trigeminal. Resultados. Se encontraron 329 documentos para su análisis, con base en este sustento bibliográfico se delinearon estos parámetros de práctica.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Merskey H. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions. Pain 1986; S-3: 345-56.

  2. Merskey H. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. International Association for the Study of Pain. Task force on taxonomy. IASP press; 1994.

  3. Dworkin RH, Backonja MM, Robotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell CM, et al. Advances in neuropathic pain: Diagnosis, mechanisms and treatment recommendations. Arch Neurol 2003; 60: 1524-34.

  4. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol 2001; 429: 1-11.

  5. Dworkin RH. An overview of neuropathic pain: Syndromes, symptoms, signs, and several mechanisms. Clin J Pain 2002; 18: 343-9.

  6. Bennett GJ. Neuropathic pain: an overview. In: Borsook D, ed. Molecular neurobiology of pain. Seattle, WA: IASP Press; 1997, pp. 109-13.

  7. Schmader KE. Epidemiology and impact in Quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18: 350-4.

  8. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar C, Cravioto P, et al. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Cuernavaca, Morelos, México; Instituto Nacional de Salud Pública; 2003.

  9. Aguilar-Salinas CA, Velazquez-Monroy O, Gómez-Peres FJ, González-Chavez A, Lara-Esqueda A, Molina-Cuevas V, et al. Characteristics of patients with type 2 diabetes in Mexico. Diabet Care 2003; 26: 2021-6.

  10. Browsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: A retrospective in the elderly population. Eur J Pain 1999; 3: 335-42.

  11. Bridges D, Thompson SWN, Rice ASC. Mechanisms of neuropathic pain. Br J Anest 2001; 87: 12-26.

  12. Ashburn MA, Caplan RA, Connis RT, Ginsberg B, Green CR, Arbor A, et al. Practice guidelines for acute pain management in the perioperative setting: An updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology 2004; 100: 1573-81.

  13. Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Assoc J 1979; 121: 1193-1254.

  14. Woolf SH, Battista RN, Anderson GM, et al. Assessing the clinical effectiveness of preventative maneuvers: analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol 1990; 43: 891-905.

  15. US Preventive Services Task Force. Screening for adolescent idiopathic scoliosis: review article. JAMA 1993; 269: 2667-72.

  16. U.S. Preventive Services Task Force Ratings: Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services. Third Edition. Periodic Updates, 2000-2003. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/3rduspstf/ratings.htm

  17. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ, Cook RJ. Users’ guides to the medical literature: IX: A method for grading health care recommendations. JAMA 1995; 274: 1800-4.

  18. Guevara-López U, Moyao-García D. Parámetros de práctica para el manejo del dolor agudo perioperatorio. Rev Mex Anest 2002; 25: 277-88.

  19. Guevara-López U, Covarrubias-Gómez A, DeLille-Fuentes R, Hernández-Ortíz A, Carrillo-Esper R, Moyao-García D. Parámetros de práctica para el manejo del dolor agudo perioperatorio. Cir Cir 2005; 73: 223-32.

  20. National Health and Medical Research Council. Acute Pain Management: Scientific Evidence. Canberra, Australia: NHMRC; 1999.

  21. Galer BS, Jensen MP. Development and preliminary validation of pain measure specific to neuropathic pain: The neuropathic pain scale. Neurology 1997; 48: 332-8.

  22. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associates with nervous or somatic lesions an development of a new neuropathic pain diagnostic questionnaire (DN-4). Pain 2005; 114: 29-36.

  23. Ramunssen PV, Sinderup SH, Jensen TJ, Bach FW. Symptoms and signs in patients with suspected neuropathic pain. Pain 2004; 110: 461-9.

  24. Simmons Z, Feldman EL. Update on diabetic neuropathy. Curr Opin Neurol 2002; 15: 595-603.

  25. Mendell JR, Sahenk Z. Painful sensory neuropathy. N Engl J Med 2003; 348: 1243-55.

  26. Podwall D, Gooch C. Diabetic neuropathy: Clinical features, etiology and treatment. Curr Neurol Neurosci 2004; 4: 55-61.

  27. Tenser R. Trigeminal neuralgia: Mechanisms and treatment. Neurology 1998; 51: 17-19.

  28. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain 2001; 124: 2347-60.

  29. Zakrzewska JM. Diagnosis and differential diagnosis of trigeminal neuralgia. Clin J Pain 2002; 18: 14-21.

  30. Ali JM, Gebarski S, Thompson BG. Transient magnetic resonance imaging signal alterations in the brainstem after microvascular decompression for trigeminal neuralgia: case report. Neurosurgery 2004; 55: E1023-E1026.

  31. Chavez-Chavez GR, De Salles AAF, Solberg TD, Pedroso A, Espinosa D, Villablanca P. Three-dimensional fast imaging employing steady-state acquisition magnetic resonance imaging for sterotactic radiosurgery of trigeminal neuralgia. Neurosurgery 2005; 56: E628.

  32. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BJM 2003; 326: 748-50.

  33. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med 2002; 347: 340-6.

  34. Feldman EL, Russell JW, Sullivan KA, Golovoy D. New insights into the pathogenesis of diabetic neuropathy. Corr Opin Neurol 1999; 12: 553-63.

  35. Verrotti A, Giuva T, Morgese G, Chiarelli F. New trend in the etiopathogenesis of diabetic neuropathy. J Child Neurol 2001; 16: 389-94.

  36. Diabetic control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.

  37. Diabetic control and complications trial research group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-8.

  38. Rull JA, Quibrera R, González-Millán H, Lozano-Castañeda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine: double-blind crossover study. Diabetología 1969; 5: 215-20.

  39. Wilton T. Tegretol in the treatment of diabetic neuropathy. Afr Med J 1974; 27: 869-72.

  40. Gómez-Pérez FJ, Choza R, Ríos JM, Reza A, Huerta E, Aguilar CA, Rull JA. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy. Arch Med Res 1996; 27: 525-9.

  41. Beydoun A, Kobetz SA, Carrazana EJ. Efficacy of oxcarbazepine in the treatment of painful diabetic neuropathy. Clin J Pain 2004; 20: 174-8.

  42. Chadda VS, Mathur M. double-blind effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 1978; 26: 403-6.

  43. Saudek CD, Werns S, Reidenberg MM. Phenytoin in the treatment of diabetic symmetrical neuropathy. Clin Pharmacol Ther 1977; 22: 196-99.

  44. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: A randomized, controlled study. Neurology 2001; 57: 505-9.

  45. Backonja M, Beydoun A, Edwards KR, Shwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. J Am Med Assoc 1998; 280: 1831-6.

  46. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999; 66: 251-2.

  47. Tamez-Perez HE, Rodriguez AM, Gomez DO. Use of gabapentin on neuropathic diabetic pain. Med Intern Mex 1998; 14: 251-3.

  48. Backonja MM. Use of anticonvulsivants for treatment of neuropathic pain. Neurology 2002; 59: S14-S17.

  49. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999; 159: 1931-7.

  50. Dallocchio C, Buffa C, Mazzarello P, Chiroli S. Gabapentin vs. amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000; 20: 280-5.

  51. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110: 628-38.

  52. Backonja MM, Serra J. Pharmacologic management part 1: better-studied neuropathic pain diseases. Pain Med 2004; 5: S28-S47.

  53. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326: 1250-6.

  54. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, Dubner R. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37: 589-96.

  55. Sindrup SH, Gram LF, Brøsen K, Eshøj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990; 42: 135-44.

  56. Sindrup SH, Gram LF, Skjold T, Grodum E, Brosen K, Beck- Nielsen H. Clomipramine vs. desipramine vs. placebo in the treatment of diabetic neuropathy symptoms: A double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683-91.

  57. Sindrup SH, Jensen TS. Pharmacologic treatment of pain in polyneuropathy. Neurology 2000; 55: 915-20.

  58. Harati Y, Gooch C, Swenson M, Edelman S, Greene D, Raskin P, et al. Double-blinded randomized trial of tramadol for the treatment of pain of diabetic neuropathy. Neurology 1998; 50: 1842-6.

  59. Jung BF, Johnson RW, Griffin DRJ, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545-51.

  60. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia. An evidence-based report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2004; 6: 959-65.

  61. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996; 335: 32-42.

  62. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93-5.

  63. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10: 177-82.

  64. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896-900.

  65. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. BMJ 1986; 293: 1529-32.

  66. Whitley RJ, Weiss H, Gnann J, et al. The efficacy of steroid and acyclovir therapy of herpes zoster in the elderly. J Invest Med 1995; 43: 252A.

  67. Huff JC, Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85: 84-9.

  68. Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85: 79-83.

  69. Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970; 211: 1681-3.

  70. Clemmensen OJ, Andersen KE. ACTH versus prednisone and placebo in herpes zoster treatment. Clin Exp Dermatol 1984; 9: 557-63.

  71. Keczkes K, Basheer AM. Do corticosteroids prevent post-herpetic neuralgia? Br J Dermatol 1980; 102: 551-5.

  72. Opstelten W, Van Wijck AJM, Stolker RJ. Interventions to prevent post herpetic neuralgia: cutaneous and percutaneous techniques. Pain 2004; 107: 202-6.

  73. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837-42.

  74. Rice ACS, Maton S. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain 2001; 94: 215-24.

  75. Sabatowsky R, Galván R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M. Pregabaline reduces pain and improves sleep and mood disturbances in patients with postherpetic neuralgia: results of a randomized, placebo-controlled clinical trial. Pain 2004; 109: 26-35.

  76. Dworkin RH, Corbin AE, Young JP, Jr., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60: 1274-83.

  77. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427-32.

  78. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671-3.

  79. Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000; 16: 188-92.

  80. Watson CPN, Chipman M, Reed K, Evans RJ, Birkett N. Amitriptyline versus maprotiline in postherpetic neuralgia: A randomized, double-blind, crossover trial. Pain 1992: 48: 29-36.

  81. Watson CPN, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: A randomized trial. Neurology 1998; 51: 1166-71.

  82. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: A randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837-41.

  83. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2002; 59: 1015-21.

  84. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in postherpetic neuralgia: A randomized, double-blind, placebo-controlled trial. Pain 2003; 104: 323-31.

  85. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64: 937-47.

  86. Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993; 15: 510-26.

  87. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy. Drugs 2000; 60: 1029-52.

  88. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002; 18: 22-7.




2020     |     www.medigraphic.com